GARNL3

Across TCGA pan-cancer cohorts, GARNL3 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated GARNL3 data layer compared with 27 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher GARNL3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GARNL3 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

LSCC and GBM are the cancer types where GARNL3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	III,IV	0.440	0.895	.010	8	view →
GBM	DFS	Quartile	All	0.907	0.561	.003	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

GARNL3–LSCC (DFS)

Open the LSCC breakdown →